ArticleNanotheranostics2022
Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis.
Open access · goldAbstract read
In one paragraph
Article in Nanotheranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Glutamate carboxypeptidase II activation in astrocytes mediates glymphatic impairment and cognitive vulnerability in the aging brain following surgery.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- N-acetyl-aspartyl-glutamate connects neuroinflammatory signatures to attention and working memory in people with HIV.AIDS (London, England) · 2026Article
- Article
- Post-methamphetamine working memory decline predicts relapse vulnerability in rats and is rescued by mGlu3 receptor activation.Psychopharmacology · 2026Article
- The potential of academic drug discovery: successes and challenges.Expert opinion on drug discovery · 2025Article
- Stress and Inflammation Target Dorsolateral Prefrontal Cortex Function: Neural Mechanisms Underlying Weakened Cognitive Control.Biological psychiatry · 2025Review
- Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function.Advances in pharmacology (San Diego, Calif.) · 2025Review
- Mass spectrometry-guided discovery of novel GCPII inhibitor scaffolds.Frontiers in pharmacology · 2025Article
- Biomaterial strategies for regulating the neuroinflammatory response.Materials advances · 2024Review
- Discovery of 2-deoxy glucose surfaced mixed layer dendrimer: a smart neuron targeted systemic drug delivery system for brain diseases.Theranostics · 2024Article
- Targeting glutamate carboxypeptidase II in IBD.Advances in pharmacology (San Diego, Calif.) · 2024Review
- Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer's disease mouse model.Translational neurodegeneration · 2023Article
- Adverse Effects of Non-Metallic Nanoparticles in the Central Nervous System.Materials (Basel, Switzerland) · 2023Review
- Scientific rationale for the use of α2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders.Molecular psychiatry · 2023Review
- Systemic Dendrimer-Peptide Therapies for Wet Age-Related Macular Degeneration.Pharmaceutics · 2023Article
- Multifaceted nanoparticles: emerging mechanisms and therapies in neurodegenerative diseases.Brain : a journal of neurology · 2023Review
- Scientific Rationale for the Treatment of Cognitive Deficits from Long COVID.Neurology international · 2023Review
- Nanomaterial payload delivery to central nervous system glia for neural protection and repair.Frontiers in cellular neuroscience · 2023Review
- Dendrimer-Conjugated Glutamate Carboxypeptidase II Inhibitor Restores Microglial Changes in a Rabbit Model of Cerebral Palsy.Developmental neuroscience · 2023Article
- Inhibition of glutamate-carboxypeptidase-II in dorsolateral prefrontal cortex: potential therapeutic target for neuroinflammatory cognitive disorders.Molecular psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Kristen R HollingerJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, USA.
Anjali SharmaCenter for Nanomedicine, Department of Ophthalmology, Johns Hopkins University, Baltimore, MD, USA.
Carolyn TallonJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, USA.
Lyndah LovellJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, USA.
Ajit G ThomasJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, USA.
Xiaolei ZhuJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, USA.
Robyn WisemanDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, MD, USA.
Ying WuJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, USA.
Siva P KambhampatiCenter for Nanomedicine, Department of Ophthalmology, Johns Hopkins University, Baltimore, MD, USA.
Kevin LiawCenter for Nanomedicine, Department of Ophthalmology, Johns Hopkins University, Baltimore, MD, USA.
Rishi SharmaCenter for Nanomedicine, Department of Ophthalmology, Johns Hopkins University, Baltimore, MD, USA.
Camilo RojasJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, USA.
Rana RaisJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, USA.
Sujatha KannanCenter for Nanomedicine, Department of Ophthalmology, Johns Hopkins University, Baltimore, MD, USA.
Rangaramanujam M KannanCenter for Nanomedicine, Department of Ophthalmology, Johns Hopkins University, Baltimore, MD, USA.
Barbara S SlusherJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, USA.
Johns Hopkins University · USJohns Hopkins Medicine · USKennedy Krieger Institute · US
Funding
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1MTargeting glutamate carboxypeptidase in perinatal brain injuryR01NS093416 · NINDS · JOHNS HOPKINS UNIVERSITY · PI Sujatha Kannan, Kannan Rangaramanujam · 2016 to 2026
$4.8MDevelopment of GCPII inhibitors for the treatment of age-related cognitive disordersR01AG068130 · NIA · JOHNS HOPKINS UNIVERSITY · PI ARNSTEN, AMY F.T., SLUSHER, BARBARA STAUCH · 2020 to 2024
$3.8MPharmacology and Molecular Sciences Training Program: Enhancing Inclusivity Through Universal Design for Learning in Graduate CoursesT32GM135083 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Caren L. Freel Meyers · 2020 to 2026
$3.3MExploring a natural product to modulate aberrant gut bacterial-fungal interactions as pathological mechanisms underlying HIV-associated depressionK01AT010984 · NCCIH · JOHNS HOPKINS UNIVERSITY · PI ZHU, XIAOLEI · 2020 to 2024
$676kNCATS NIH HHS UL1 TR001079NCCIH NIH HHS K01 AT010984NIA NIH HHS R01 AG068130NIGMS NIH HHS T32 GM135083NINDS NIH HHS R01 NS093416
Abstract
Cognitive impairment is a common aspect of multiple sclerosis (MS) for which there are no treatments. Reduced brain
Indexed as
DendrimersMultiple SclerosisAnimalsCognitionDisease Models, AnimalMiceMicrogliaDendrimerscognitive impairmentdendrimerGCPIImultiple sclerosisNAAG
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.